Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Publication Information:
      Dove Medical Press, 2018.
    • Publication Date:
      2018
    • Collection:
      DOAJ-Articles_enriched
      DOAJ-Articles
    • Abstract:
      MosheAshkenazi,1,2SaraySity,2 IfatSarouk,1,2Bat El Bar Aluma,1,2AdiDagan,1,2YaelBezalel,1,2LeaBentur3 KrisDe Boeck,4 OriEfrati1,2 1Pediatric Pulmonology and National CF Center, Edmond and Lilly Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Pediatric Pulmonology Institute, Ruth Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; 4Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgium Background: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Previous studies reported borderline results when treating ABPA with omalizumab. Methods: A retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing. Results: The database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes. Conclusion: No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed. Keywords: ABPA, Omalizumab, CF, IgE
    • Accession Number:
      pmc: PMC6016275
      pmid: 29950869
    • File Description:
      text/html
    • ISSN:
      1178-6965
    • Accession Number:
      10.2147/JAA.S156049
    • Accession Number:
      edsair.dedup.wf.001..959d97be3183dd4623934a72a4dffc75
  • Citations
    • ABNT:
      ASHKENAZI, M. et al. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Journal of Asthma and Allergy, [s. l.], v. 11, 2018. DOI 10.2147/JAA.S156049. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsair&AN=edsair.dedup.wf.001..959d97be3183dd4623934a72a4dffc75&custid=s8280428. Acesso em: 10 jul. 2020.
    • AMA:
      Ashkenazi M, Sity S, Sarouk I, et al. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Journal of Asthma and Allergy. 2018;11. doi:10.2147/JAA.S156049.
    • AMA11:
      Ashkenazi M, Sity S, Sarouk I, et al. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Journal of Asthma and Allergy. 2018;11. doi:10.2147/JAA.S156049
    • APA:
      Ashkenazi, M., Sity, S., Sarouk, I., Bar Aluma, B. E., Dagan, A., Bezalel, Y., Bentur, L., De Boeck, K., & Efrati, O. (2018). Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Journal of Asthma and Allergy, 11. https://doi.org/10.2147/JAA.S156049
    • Chicago/Turabian: Author-Date:
      Ashkenazi, Moshe, Saray Sity, Ifat Sarouk, Bat El Bar Aluma, Adi Dagan, Yael Bezalel, Lea Bentur, Kris De Boeck, and Ori Efrati. 2018. “Omalizumab in Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis.” Journal of Asthma and Allergy 11 (June). doi:10.2147/JAA.S156049.
    • Harvard:
      Ashkenazi, M. et al. (2018) ‘Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis’, Journal of Asthma and Allergy, 11. doi: 10.2147/JAA.S156049.
    • Harvard: Australian:
      Ashkenazi, M, Sity, S, Sarouk, I, Bar Aluma, BE, Dagan, A, Bezalel, Y, Bentur, L, De Boeck, K & Efrati, O 2018, ‘Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis’, Journal of Asthma and Allergy, vol. 11, viewed 10 July 2020, .
    • MLA:
      Ashkenazi, Moshe, et al. “Omalizumab in Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis.” Journal of Asthma and Allergy, vol. 11, June 2018. EBSCOhost, doi:10.2147/JAA.S156049.
    • Chicago/Turabian: Humanities:
      Ashkenazi, Moshe, Saray Sity, Ifat Sarouk, Bat El Bar Aluma, Adi Dagan, Yael Bezalel, Lea Bentur, Kris De Boeck, and Ori Efrati. “Omalizumab in Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis.” Journal of Asthma and Allergy 11 (June 1, 2018). doi:10.2147/JAA.S156049.
    • Vancouver/ICMJE:
      Ashkenazi M, Sity S, Sarouk I, Bar Aluma BE, Dagan A, Bezalel Y, et al. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Journal of Asthma and Allergy [Internet]. 2018 Jun 1 [cited 2020 Jul 10];11. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsair&AN=edsair.dedup.wf.001..959d97be3183dd4623934a72a4dffc75&custid=s8280428